H.C. Wainwright Reiterates a Buy Rating on Rigel Pharmaceuticals (RIGL), Sets a $57 PT
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is one of the top most undervalued biotech stocks to buy now. On August 6, analyst Joseph Pantginis from H.C.
Rigel Pharmaceuticals Inc (RIGL)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Armistice Capital Steven Boyd | 1,600,000 | $29,968,000 | +6% | 0.52% |
| 2. | Soleus Capital Guy Levy | 658,145 | $12,327,056 | -42% | 0.82% |
| 3. | Marshall Wace LLP Paul Marshall And Ian Wace | 368,950 | $6,910,434 | +75% | 0.01% |
| 4. | Renaissance Technologies Jim Simons | 236,446 | $4,428,634 | +18% | 0.01% |
| 5. | Squarepoint Ops LLC Maxime Fortin (Cio) | 36,215 | $678,307 | +65% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.69 | 1,000,000 | $688,400.00 | 1,391,776 | 2022-06-09 | Filing | |
| $2.13 | 3,274 | $6,971.00 | 50,000 | 2019-05-22 | Filing | |
| $2.13 | 46,726 | $99,573.11 | 46,726 | 2019-05-22 | Filing | |
| $3.23 | 50,000 | $161,340.00 | 215,000 | 2018-09-11 | Filing | |
| $3.28 | 50,000 | $164,210.00 | 165,000 | 2018-09-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $21.93 | 1,734 | $38,019.68 | 57,235 | 2025-02-05 | Filing | |
| $20.92 | 2,036 | $42,595.16 | 58,969 | 2025-02-04 | Filing | |
| $21.93 | 1,796 | $39,379.10 | 51,704 | 2025-02-05 | Filing | |
| $20.92 | 2,125 | $44,457.13 | 53,500 | 2025-02-04 | Filing | |
| $21.93 | 4,400 | $96,474.40 | 239,454 | 2025-02-05 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,625,770 | $30,450,672 | 0% | |
| 2. | 1,052,871 | $19,720,274 | 0% | |
| 3. | 600,181 | $11,241,390 | 0% | |
| 4. | 591,553 | $11,079,788 | 0.08% | |
| 5. | 415,607 | $7,785,775 | 0% |
News See All
10 Most Undervalued Biotech Stocks to Buy Now
On July 25, Salveen Richter, Goldman Sachs' lead biotech analyst, appeared on CNBC’s ‘Squawk Box’ to talk about the state of the biotech sector and what to expect from the earnings season, among...
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q2 2025 Earnings Call Transcript
Operator: Greetings, and welcome to Rigel Pharmaceuticals Financial Conference Call for the Second Quarter 2025. [Operator Instructions] As a reminder, this conference is being recorded.
H.C. Wainwright Reiterates a Buy Rating on Rigel Pharmaceuticals (RIGL)
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On June 3, H.C.
13 Cheap Healthcare Stocks with Huge Upside Potential
On July 8, Kate Moore, Citi Wealth CIO, appeared on CNBC's 'Squawk Box' to talk about the recent rally in equities.
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q1 2025 Earnings Call Transcript
Operator: Greetings, and welcome to Rigel Pharmaceuticals Financial Conference Call for the First Quarter 2025. [Operator Instructions] As a reminder, this conference is being recorded.
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q4 2024 Earnings Call Transcript
Operator: Greetings, and welcome to Rigel Pharmaceuticals' financial conference call for the fourth quarter and full year 2024. At this time, all participants are in a listen-only mode.
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q3 2024 Earnings Call Transcript
Operator: Greetings and welcome to Rigel Pharmaceutical's Financial Conference Call for the Third Quarter 2024. At this time, all participants are in a listen-only mode.
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q2 2024 Earnings Call Transcript
Operator: Greetings and welcome to Rigel Pharmaceutical's Financial Conference Call for the Second Quarter 2024. At this time, all participants are in a listen-only mode.
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q1 2024 Earnings Call Transcript
Operator: Greetings and welcome to Rigel Pharmaceuticals Financial Conference Call for the First Quarter 2024. At this time, all participants are in a listen-only mode.
Billionaire Hedge Funds
